Protocol Service
Peptide Therapy
CJC-1295 Peptide Therapy in Scarsdale, NY
Protocol Health prescribes CJC-1295, a compounded GHRH analog that raises your own growth hormone and IGF-1, at our Scarsdale, NY clinic under physician supervision. Its human studies are small and short, and the FDA has reported serious adverse events, which your provider explains first.
Consultation $249, or $349 with blood work.
CJC-1295 has never been FDA-approved for any use, so prescribing it is unapproved rather than off-label. The FDA lists serious adverse events with CJC-1295, including increased heart rate and a systemic vasodilatory reaction.
Medically reviewed by Richard Dentico, MD, Medical Director
★ 5.0 on Google · 107 reviews (as of October 2026) · Physician-led, family-owned
Our Scarsdale clinic serves Westchester County. Telehealth in NY, NJ, CT, FL and CA.
Book Now
CJC-1295 at Protocol Health
Before you book
What is CJC-1295?
CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH). It prompts the pituitary to release more of its own growth hormone, which raises IGF-1. Its human safety data come from studies lasting weeks, and there are no outcome trials, so it is considered carefully and with baseline labs.
Who asks about CJC-1295?
Adults interested in growth hormone-releasing peptides who accept limited evidence.
- Interested in GH-releasing peptides under supervision
- Willing to have baseline and follow-up labs
- Understand there are no outcome trials
CJC-1295 safety and evidence
Small, short human studies.
Status. Never FDA-approved; compounded in the US.
Safety. The FDA has flagged compounded CJC-1295 for immune reactions and impurities and reported increased heart rate and a vasodilatory reaction.
Evidence. Human data from studies lasting weeks; no outcome trials.
How CJC-1295 care works
Labs first. Baseline labs, including IGF-1 where useful, before any prescription.
Risks stated. The FDA's adverse-event reports are explained before you decide.
Alternatives. Sermorelin and tesamorelin work on the same pathway with different evidence.
Follow-up. Labs and check-ins decide whether to continue.
Starting CJC-1295
Consult, labs, decision.
- Consultation. Goals and history.
- Baseline labs. Drawn at the Scarsdale clinic or near home.
- Decision. CJC-1295, an alternative, or nothing.
- Monitoring. Follow-up labs and check-ins.
Common questions
CJC-1295: frequently asked questions
Is CJC-1295 FDA-approved?
No. CJC-1295 has never been FDA-approved for any use.
What does CJC-1295 do?
It prompts the pituitary to release more growth hormone, which raises IGF-1.
Are there safety concerns?
Yes. The FDA lists serious adverse events with CJC-1295, including increased heart rate and a vasodilatory reaction.
How is it different from sermorelin?
Both are GHRH analogs; they differ in structure, how long they act and their evidence and FDA history.
Contact Us
Book Your Appointment Today
Fill out the form below to schedule your visit with our expert team.